Teva expands biosimilar portfolio with Polpharma and Samsung deals

Under the terms of the deal, Polpharma Biologics maintains primary control over the development and manufacturing of the ocrelizumab biosimilar. Teva steps in to handle the regulatory pathways and subsequent commercial rollout across a broad international map, including the U.S., Europe, Brazil, Canada, Australia, New Zealand, Israel, and Turkey. The medication targets the central nervous system, addressing a chronic disease that affects the brain, spinal cord, and optic nerves.

Simultaneously, the company is pushing into ophthalmology through a separate agreement with Samsung Bioepis. Teva will launch Opuviz in Canada, an approved biosimilar injection designed to treat severe retinal eye diseases. These parallel moves signal a aggressive shift toward high-value biosimilar assets as the company seeks to diversify its revenue streams beyond traditional generics.